Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure.

Gregor PoglajenJus KselaSabina FrljakGregor ZemljicElizabeta Boznar AlicAndraz CerarBojan Vrtovec

Published in: Disease markers (2019)

In patients with chronic heart failure undergoing CD34+ cell therapy, a decrease in galectin-3 plasma levels is associated with beneficial response to this treatment modality. Further prospective data is warranted to confirm our findings and to deepen our understanding of the role of gal-3 in the field of stem cell therapy.

Keyphrases

cell therapy
stem cells
mesenchymal stem cells
ejection fraction
nk cells
electronic health record
big data
machine learning
bone marrow
combination therapy
artificial intelligence